Russell Schundler Sells 2,060 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 2,060 shares of Liquidia stock in a transaction dated Friday, April 12th. The stock was sold at an average price of $14.58, for a total value of $30,034.80. Following the completion of the transaction, the general counsel now owns 486,027 shares in the company, valued at approximately $7,086,273.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Russell Schundler also recently made the following trade(s):

• On Monday, March 18th, Russell Schundler sold 8,653 shares of Liquidia stock. The stock was sold at an average price of $15.82, for a total value of $136,890.46.

Liquidia Stock Performance

Shares of NASDAQ:LQDA opened at $13.81 on Friday. Liquidia Co. has a 1 year low of $5.71 and a 1 year high of $16.99. The stock’s 50-day moving average is $14.75 and its 200 day moving average is $10.95.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings data on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). The firm had revenue of $4.53 million for the quarter, compared to the consensus estimate of $5.29 million. Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. As a group, analysts forecast that Liquidia Co. will post -1.01 EPS for the current fiscal year.

Institutional Trading of Liquidia

Large investors have recently bought and sold shares of the company. LB Partners LLC bought a new stake in Liquidia during the 4th quarter valued at approximately $3,404,000. Vanguard Group Inc. boosted its position in Liquidia by 1.0% during the 3rd quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock valued at $17,590,000 after acquiring an additional 26,678 shares in the last quarter. Strs Ohio bought a new stake in Liquidia during the 3rd quarter valued at approximately $507,000. Fortitude Family Office LLC bought a new stake in Liquidia during the 4th quarter valued at approximately $26,000. Finally, Aigen Investment Management LP bought a new stake in shares of Liquidia in the 3rd quarter worth approximately $80,000. 64.54% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LQDA has been the topic of several analyst reports. Bank of America lifted their price objective on Liquidia from $13.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, December 21st. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Liquidia in a report on Wednesday, April 10th. Wedbush reiterated an “underperform” rating and issued a $3.00 price objective on shares of Liquidia in a report on Thursday, December 21st. HC Wainwright boosted their price target on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, March 14th. Finally, LADENBURG THALM/SH SH boosted their price target on Liquidia from $15.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Liquidia presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).